Clinical Core

The availability of biological samples from individuals with alcoholic liver disease (ALD), as well as samples from appropriate heavy drinking, yet healthy controls and non-drinking healthy controls, is an essential first step in the translation of basic research advances to the clinic.

The  Clinical Core of the Cleveland Alcohol Center can provide CAC investigators to access to de-identified biological samples (tissue biopsy, plasma/serum, urine, DNA and peripheral blood mononuclear cells (PBMCs)  from patients with different stages of alcoholic liver disease, as well as healthy control subjects. 

Samples are limited and approval for use must be obtained from the CAC executive committee after review of investigator’s proposal.  Please contact Dr. Arthur McCullough ( or Laura Nagy ( to apply for use of our Clinical Core.

De-identified clinical/biological samples are available from the following three biorepositories:

  1. CoPath Database/Biospecimen Repository:  The CoPath Database/Biospecimen Repository at the Cleveland Clinic allows investigators access to archived biopsy materials initially used for diagnostic purposes.  Repository also has access to clinical information related to the case history of each patient, as well as follow-up clinical data on response to therapy.

  2. CCF ALD biorepository: The CCF ALD biorepository includes samples of serum, plasma and DNA from patients with different stages of ALD collected since 2012.  Currently, the biorepository contains samples from approximately 120 patients.  Relevant clinical information for each patient is available.  Samples are also available from about 20 subjects who are heavy drinkers without ALD, recruited from the Cleveland Clinic alcohol use disorder treatment clinic.
  3. CASH registry:  The Case Alcoholic SteatoHepatitis (CASH) registry aims to understand the natural history of severe Alcoholic Steatohepatitis (ASH) in clinical practice, as well as the impact of currently used interventions on the short and long term outcomes of this disease. The registry recruits inpatients admitted with the diagnosis of severe ASH and follows them at pre-determined intervals up to 365 days. Serial samples of serum, plasma and urine, as well as DNA are available. Clinical, nutritional and biochemical data collected from the CASH registry are available, as well as data on alcohol recidivism.